Disclosure pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The promoter and promoter group of Ind-Swift Laboratories Limited acquired 45,15,495 equity shares (5.53% of the company's share capital) pursuant to a scheme of amalgamation of Ind-Swift Limited (Transferor Company) with Ind-Swift Laboratories Limited (Transferee Company). The shares were allotted on August 25, 2025, increasing the company's equity share capital from INR 73.49 crores to INR 81.61 crores. As a result, the promoter group's aggregate holding rose from 37.72% (2,77,18,783 shares) to 39.50% (3,22,34,278 shares) of the total share capital. Essix Biosciences Limited, the flagship promoter entity, individually increased its holding from 34.33% to 34.04% on a fully diluted basis.
This is a non-cash, scheme-based share issuance to promoter group entities as consideration for the merger of Ind-Swift Limited into the listed company. The promoter group's voting control is now stronger at 39.50%, though still well below 50%, so no change-of-control concerns arise. No fresh equity was issued to public shareholders, so there is no dilution impact for existing public investors.